Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared on X:
“This is not really a paper about ixazomib.
Although 6,600 patients with myeloma have been enrolled in ixazomib clinical trials, we still do not know if ixazomib has non-inferior efficacy or safety compared to its predecessors, bortezomib and carfilzomib.”
Title: Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis
Authors: Veer Shah, Darshi Shah, Payton Utzman, Karan Shah, Srivatsan Swaminathan, Maria Mainou, Rajshekhar Chakraborty, Aaron Goodman, Samer Al Hadidi, Amar H. Kelkar, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin
Read the Full Article
